h9 human embryonic stem cells hescs  (WiCell Research Institute Inc)

Journal: Blood Advances

Article Title: Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity

doi: 10.1182/bloodadvances.2025017707

Figure Lengend Snippet: Evolution of licensing ligand expression and licensing phenotype after h-HSCT. (A) Normalized expression of total HLA class I, HLA-C, and HLA-E over time. Median fluorescence intensity (MFI) normalized to isotype control for total HLA class I, HLA-C, and HLA-E on total lymphocytes, T cells (CD3 + CD56 − CD19 − ), and NK cells (CD3 − CD56 + ) at each time point. Data are presented as box plots with overlaid individual values and density plots. Comparisons between time points were performed using Wilcoxon test. (B) Study design; peripheral blood samples were collected from h-HSCT recipients at the indicated time points. Donor (D) and recipient (R) combinations were identified based on the presence (+) or absence (−) of HLA-C C1 or C2 ligands and degranulation of NKG2A + KIR − , NKG2A − KIR − , NKG2A − KIR2DL1 single+ , and NKG2A − KIR2DL2/3 single+ NK cell subsets was evaluated after coculture with the HLA class I−negative 721.221 cell line. (C) Correlation between degranulation of KIR − NKG2A + NK cells and normalized MFI of HLA-E (on total lymphocytes) at each time point. Spearman correlation coefficients and P values are indicated. Linear regression with 95% CI is shown. (D-E) Paired comparison of degranulation of NKG2A − KIR − and NKG2A − KIR2DL1 single+ (D) or KIR2DL2/3 single+ (E) NK cell subsets according to D and R HLA-C combinations at each time point. Data are presented as paired comparisons with individual values. Paired comparisons were performed using Wilcoxon signed-rank test. ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001; ∗∗∗∗ P < .0001.

Article Snippet: NK cell cytotoxic potential was evaluated by CD107a expression after 5-hour coculture with 4 hematological malignancy cell lines: H9 (T-cell non-Hodgkin lymphoma, ATCC HTB-176), MOLT-4 (T-cell acute lymphoblastic leukemia, ATCC CRL-1582), KG-1 (acute myeloblastic leukemia [AML], ATCC CCL-246), and NB4 (AML, DSMZ ACC 207).

Techniques: Expressing, Fluorescence, Control, Comparison

Journal: Biofabrication

Article Title: Collagen hydrogel tube microbioreactors for cell and tissue manufacturing

doi: 10.1088/1758-5090/ae2718

Figure Lengend Snippet: Culturing human embryonic stem cells in ColTubes. (A) Phase-contrast images of H9 hESCs cultured in ColTubes at days 0, 1, 3, 5, and 7. (B) Live/Dead staining of H9 cells inside the tubes and released from the tubes on day 7. (C) Flow cytometry analysis shows that 99.6% of cells harvested on day 7 are Calcein AM-positive (live cells). (D) Flow cytometry analysis confirms that majority cells on day 7 express pluripotency markers OCT4 and Nanog.

Article Snippet: For a typical cell culture, H9 human embryonic stem cells (hESCs) (WA09, WiCell) loaded in 20 μ l ColTubes were suspended in 2 ml Essential 8 medium (Gibco) supplemented with 10 μ M Y-27632 (Sigma) in a 6-well plate and incubated at 37 °C with 5% CO2 and 21% O2.

Techniques: Cell Culture, Staining, Flow Cytometry

Journal: Biofabrication

Article Title: Collagen hydrogel tube microbioreactors for cell and tissue manufacturing

doi: 10.1088/1758-5090/ae2718

Figure Lengend Snippet: Differentiating H9 hESCs into Cardiomyocytes in ColTubes. (A) The cardiomyocyte production protocol. H9 hESCs are processed into ColTubes and expanded in E8 medium, followed by mesoderm induction for 1 d, cardiomyocyte differentiation from days 2–11, and metabolic enrichment from days 11–18. (B) Phase-contrast and fluorescent images of cells in ColTubes on days 0, 1, 3, 5, 7, 11, 15, and 18. Cardiomyocytes are cTnT-positive.

Article Snippet: For a typical cell culture, H9 human embryonic stem cells (hESCs) (WA09, WiCell) loaded in 20 μ l ColTubes were suspended in 2 ml Essential 8 medium (Gibco) supplemented with 10 μ M Y-27632 (Sigma) in a 6-well plate and incubated at 37 °C with 5% CO2 and 21% O2.

Techniques: